Hutchinson validates StO2 monitor in trauma setting:
This article was originally published in Clinica
Executive Summary
Hutchinson Technology says that a clinical trial has confirmed the value of using its noninvasive InSpectra tissue oxygen saturation (StO2) monitor in trauma patients. Local StO2 measured by the near infrared spectroscopy-based monitor on the muscle at the base of the thumb was a statistically significant indicator of inadequate blood flow in trauma patients, revealed the study of 383 severely injured people. InSpectra was cleared for sale in the US in July this year. Shipments of the device are expected to begin by the end of 2006, says the Hutchinson, Minnesota firm. The technology is indicated for use in monitoring patients during circulatory or perfusion examinations of skeletal muscle, or when there is a suspicion of compromised circulation.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.